This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquimmod or pharmaceutically acceptable salt thereof and an amount of methotrexate wherein the amounts when taken together are effective to treat the subject. This invention also provides laqumimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. ...

Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also disclosed are rasagiline citrate salt and the use and process of manufacture thereof.

The present invention provides amorphous and crystalline forms of olanzapine pamoate and processes for preparing them. The invention further provides a pharmaceutical composition comprising at least one of the described crystalline forms of olanzapine pamoate. This pharmaceutical composition may additionally comprise at least one pharmaceutically acceptable excipient. The present invention encompasses the use of at least one of the forms of olanzapine pamoate for the preparation of a formulation...

The present invention provides polymorphic forms of aliskiren hemifumarate and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1 T3 or T4 T5 T6 T7 T8 and at least one pharmaceutically acceptable excipient and the use of these pharmaceutical compositions in the treatment of hypertension.

The invention provides anhydrous forms of dasatinib methods for their preparation and pharmaceutical compositions thereof.

Formulations containing imatinib preferably imatinib mesylate with high polymorphic stability and the processes for the preparation thereof are disclosed.

Nilotinib•3HCl and its crystalline forms are described and processes for the preparation of the same.

The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystal line forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension.